In the coronavirus efficacy (COVE) phase 3 clinical trial, vaccine recipients were assessed
for neutralizing and binding antibodies as correlates of risk for COVID-19 disease and as …

Background Although the three vaccines against coronavirus disease 2019 (Covid-19) that
have received emergency use authorization in the United States are highly effective, …

Omicron Neutralization and mRNA-1273 Boosters Neutralization of the omicron variant was
assessed in serum samples obtained from persons who had received an mRNA-1273 …

The Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
exhibits reduced susceptibility to vaccine-induced neutralizing antibodies, requiring a boost to …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BA.2 sub-lineage
has gained in proportion relative to BA.1. Because spike (S) protein variations may …

Vaccine protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
infection wanes over time, requiring updated boosters. In a phase 2, open-label, …

The Antibody Mediated Prevention trials showed that the broadly neutralizing antibody (bnAb)
VRC01 prevented acquisition of human immunodeficiency virus-1 (HIV-1) sensitive to …

SARS-CoV-2 Omicron subvariants have generated a worldwide health crisis due to
resistance to most approved SARS-CoV-2 neutralizing antibodies and evasion of vaccination-…

The best assay or marker to define mRNA-1273 vaccine–induced antibodies as a correlate
of protection (CoP) is unclear. In the COVE trial, participants received two doses of the mRNA…

The Omicron variant of SARS-CoV-2 is raising concerns because of its increased
transmissibility and potential for reduced susceptibility to antibody neutralization. To assess the …